Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
about
Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.Thrombotic thrombocytopenic purpura and pregnancy: report of four cases and literature review.Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow.Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome.Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab.Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report.Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders.Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.Thrombotic thrombocytopenic purpura: survival by "giving a dam"Journey in reverse: TTP from bedside to blood bank to bench.Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience.Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.Rituximab in the treatment of autoimmune haematological disorders.Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature.Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature.Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.Sepsis-induced disseminated intravascular coagulation with features of thrombotic thrombocytopenic purpura: a fatal fulminant syndrome.[Very severe thrombotic thrombocytopenic purpura (TTP) after H1N1 vaccination].Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndromeHow I treat refractory thrombotic thrombocytopenic purpura.Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models.A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab.Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpuraSystemic Lupus Erythematosus Presenting as Refractory Thrombotic Thrombocytopenic Purpura: A Diagnostic and Management Challenge. A Case Report and Concise Review of the LiteratureThrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics.Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura.Why Do We Need ADAMTS13?Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions.Use of cellular and plasma apheresis in the critically ill patient: Part II: Clinical indications and applications.Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model.
P2860
Q33358806-52BABC49-D104-4294-8FA5-58272A47049EQ33359900-C41FC3A5-47D2-404D-A46F-A8E341C6BC18Q33360484-478600B5-DF14-4E65-9B7D-A54B79568452Q33361703-6274A539-7A07-4A0C-814E-F4A48AC8AD0EQ33362820-53A922C5-9200-456F-A10B-9FE1794DC8E1Q33364209-76A43C85-5A6C-4160-84D5-8F28B4718681Q33366172-704E524B-9336-4A7B-86C7-678CBE097C84Q33368176-3FA7E699-668C-4892-A390-8E0B7198ADEDQ33368490-1074C3F9-02C6-48CD-94AD-AEBBCFE6C2FCQ33369692-C2E128C1-4897-4525-8A5B-CC8DCF4F748DQ33369765-923698BE-9913-467F-A903-FE2ABD3EE785Q33370875-F84A661C-9ABA-4AB1-8016-60DB25A04412Q33372115-BB8FFFE9-0BCD-4F05-8CB6-4A21CD90E7FEQ33373067-E37AA9F1-885B-45F6-A4FF-F833F65E8E68Q33373368-42AB297A-B896-434D-8ECE-5C0E15157553Q33373783-440B317C-8E82-4DBE-93D7-FCF2977AB77DQ33373912-E9937FB7-7177-42F6-8996-4F55A89D8BB0Q33378854-21A6BF8C-A3A4-4621-ADE2-A8E11EE0AC2AQ33380812-D23DECCB-6273-4370-80A9-ACE5D53C47CAQ33384910-3262256D-3039-4DC7-8D10-B10C729BDE18Q33384920-BE2659B0-B7C6-4191-A931-D4C44828E326Q33388536-F3AF5B74-2EF8-4249-ACF1-F277236105DCQ33392075-B4999064-7591-43B1-9255-729B5A228898Q33397081-5942185D-C60E-4B3B-8FDB-84B4A4C631C6Q33399396-D4777C05-3C74-4EF2-BB49-0075BCB2CDD7Q33400172-A0FF0C83-8DAF-4710-9BE5-27B8728A9AEFQ33401010-3D6CF528-F97E-4091-A847-B6562E1399D5Q33409112-7F97FC83-6947-49AD-AB21-2A18E45122C8Q33412445-592133AB-A40C-46CB-BC15-3EBDB2A3A72DQ33421268-E5B49DA0-7CD0-47F0-94DD-2C279555352CQ33421373-7AED8572-C6A6-49C4-B229-8971EB4FEFC6Q33421822-032FC290-86A0-4FBB-88DB-6F8EAC4E8C4FQ33435545-9036211E-4BC9-46E0-952E-E20F4C07E1A6Q33436271-736F37DB-7F25-46C2-A850-7D498BE94E7AQ33443111-68D32451-041B-4C4F-87F7-D020C7E4A585Q34377532-2942EB76-6B0E-422E-BDB2-4810ACF3AFD7Q35062975-DCCEA842-5466-4DE6-B13C-84C115E6F7BFQ35848128-E92B878E-D436-4903-9598-D134A344449CQ36108261-D099F0B5-012B-4388-8055-C5F07B9AE98FQ36174498-F3214244-8A12-49B0-81A3-C93D6CF888AD
P2860
Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Remission of chronic thromboti ...... yclophosphamide and rituximab.
@ast
Remission of chronic thromboti ...... yclophosphamide and rituximab.
@en
type
label
Remission of chronic thromboti ...... yclophosphamide and rituximab.
@ast
Remission of chronic thromboti ...... yclophosphamide and rituximab.
@en
prefLabel
Remission of chronic thromboti ...... yclophosphamide and rituximab.
@ast
Remission of chronic thromboti ...... yclophosphamide and rituximab.
@en
P2093
P1476
Remission of chronic thromboti ...... yclophosphamide and rituximab.
@en
P2093
Arnel M Pallera
J Evan Sadler
Lawrence T Goodnough
Morey A Blinder
Xinglong Zheng
P304
P356
10.7326/0003-4819-138-2-200301210-00011
P407
P577
2003-01-01T00:00:00Z